New Delhi: Through a recent notification, National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India has announced that it will be holding a meeting for stakeholders consultation on revising the ceiling price of Coronary Stents.

NPPA fixed the ceiling prices of coronary stents vide notification dated 13th February 2017 which was valid for one year. This decision is to be revisited now during February 2018.

As per an order dated 29^th January the Authority in its meeting to be held on 05th February 2018 in the Conference Room of NPPA will hear all the stakeholders.

On 30^th January NPPA will meet eminent Intervention Cardiologists; on 5^th Feb will meet AdvaMed, MTal, AIMED, ISMA, AMCCI, AMCHAM, ASSOCHAM, CM, FICCI, PHDCC&I, Multinational stent manufacturing companies, Indian Stent manufacturing companies and ADEH, AIDAN. CAI, ORF, Oxfam India, PHFI.

SI No	Date	Time	Stakeholders
1.	30-01-2018	03.00 pm	Meeting with eminent Intervention Cardiologists

SI No	Date	Time	Stakeholders
1	05-02-2018	11.30 am	AdvaMed, MTaI
2	05-02-2018	12.15 pm	AIMED, ISMA
3	05-02-2018	02.30 pm	AMCCI, AMCHAM, ASSOCHAM, CII, FICCI, PHDCC&I,
4	05-02-2018	03.15 pm	Multinational scent manufacturing companies
5	05-02-2018	04.00 pm	Indian Stent manufacturing companies
6	05-02-2018	04.45 pm	ADEH, AIDAN, CAI, ORF, Oxfam India, PHFI,

Apart from the above-mentioned stakeholders, if any formal stakeholder has been left out and wants to put forward its views, they are requested to send an email in this regard to chairman.nppa@nic.in for getting confirmation for the meeting.

Not more than one representative of a company may be allowed.

In a memorandum dated 9 November 2017 NPPA had asked domestic and foreign stent makers to submit their representations on stent pricing by 31 December 2017. Same month Abbott Laboratories refused to introduce its latest stent Xience Sierra in India. Earlier in September, it had received permission to withdraw its premium Xience Alpine metallic stents as well as its dissolving stents.

Read also: Abbott pulls back its bioresorbable stent-ABSORB, also moves to withdraw XIENCE from India

Read also: NPPA says Abbott can discontinue Xience Alpine stent in a year, check out details

In September, US trade representative wrote to Indian commerce minister and the prime minister’s principal secretary that the policy had created serious problems for US stent makers in India. He also urged India not to extend caps to other devices. The matter was also discussed during Prime Minister Narendra Modi’s visit to Washington in June.

Below is the attachment for the same.

http://www.nppaindia.nic.in/order/Stakeholder_consultation.pdf